Tag Archives: Favipiravir

Notice of the Postponement of Announcement of Financial Results (Consolidated) for the Fiscal Year ended March 31, 2020 FUJIFILM Holdings Corporation (the “Company”) would like to express our deepest sympathy to all those who lost loved ones and those affected by COVID-19. Since it will take more time than we expected to close consolidated financial […]

CMIC Group Supports Clinical Trials and Manufacturing of Influenza Antiviral Drug “Avigan® Tablet” and Contributes to Accelerating Provision for COVID-19 Patients TOKYO–(BUSINESS WIRE)–CMIC HOLDINGS Co., Ltd. (Head Office: Tokyo, Minato-ku, Representative Director & CEO Kazuo Nakamura, hereafter “CMIC”) announced today that CMIC is providing monitoring services as a CRO (Contract Research Organization) for “Avigan® Tablet” (generic […]

Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19 TOKYO, April 15, 2020 — FUJIFILM Corporation (President: Kenji Sukeno) has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for treating patients with COVID-19. To […]

TODAY @ 1:30 PM EDT (NOW) Unpacking the Stimulus Bill for Freelancers COVID-19 has led to some unprecedented federal legislation and many freelancers have been left trying to understand how it affects them. This week’s Fujifilm Friday Forum brings you Tom Maddrey, ASMP’s General Counsel to the American Society of Media Photographers, to answer all of your […]

We announced this yesterday as part of our COVID-19 (Coronavirus) coverage the United States is now in Phase II clinical trials, while other countries are already in Phase 3. Things are moving quickly around the world and Fujifilm has been playing a big part ( 1, 2, 3, 4, 5, 6, 7, 8, 9) in the Eastern response and now the Western response […]